Whitepapers/App Notes/Posters

Article: Regulatory guidance in designing a CCI testing strategy

Posted: 6 January 2021 | | No comments yet

A summary of the current state of container closure integrity testing in the pharmaceutical industry.

Container closure integrity (CCI) plays an important role in maintaining the sterility and stability of sterile injectable products. Recent regulatory guidance has triggered changes in industry best practices in the area of CCI testing. This article summarizes the current state of container closure integrity testing in the pharmaceutical and biopharmaceutical industries and outlines possible approaches for developing a CCIT strategy.











    To read this article in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Lighthouse Instrument

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend